Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 4Active not recruiting 4Recruiting 3Completed 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 35INDUSTRY 6NIH 4OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Sarcoma, Alveolar Soft Part 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 7Magnetic Resonance Spectroscopy 7Radiotherapy 5Biopsy 4Radiation 3High-Energy Shock Waves 3Cyclophosphamide 3venetoclax 2X-Rays 2Vincristine 2Spinal Puncture 2Sentinel Lymph Node Biopsy 2Radiosurgery 2Paclitaxel 2Daunorubicin 2Cytarabine 2Azacitidine 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1taxane 1sulforaphane 1sacituzumab govitecan 1revumenib 1prednylidene 1pertuzumab 1pembrolizumab 1pegaspargase 1nelarabine 1merphos 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × NETWORK × fludarabine × Clear all
NCT07297667 2026-05-12

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Canadian Cancer Trials Group

Phase 1 Not yet recruiting
30 enrolled
BreastGenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡